Exemestane (Aromasin) [email protected]

Aromasin was first released on the U.S. market in 2000 after shortly gaining FDA approval a few months prior in 1999. The primary purpose of use as with most AI's would be to combat breast cancer in post-menopausal women. Shortly after, the AI would begin to gain a lot of popularity among anabolic steroid users for its ability to protect against estrogenic related side effects. This action is very similar to the older and more popular AI's in Arimidex and Femara It would also gain a fair amount of popularity in Post Cycle Therapy (PCT) plans among steroid users. It was not the first AI to gain such popularity but would prove to be a little more advantageous for this purpose than most AI's.

Aromasin is officially classified as a steroidal suicide Aromatase Inhibitor, and carries the ability to inhibit the aromatase enzyme, which is responsible for the production or conversion of testosterone to estrogen. Aromasin has the ability to block aromatization, which in turn inhibits the production of estrogen, and thereby lowers the body's serum estrogen levels. This will prove useful to breast cancer patients as breast cancer often feeds off the estrogen hormone. It will also prove useful to the anabolic steroid user.


Web: *
Web: *
Email: *
Skype: +8615711952876
Whatsapp +8615711952876